Fig. 1.

Magnetic resonance imaging demonstrating a partial response of a patient with recurrent atypical (grade II) meningioma following four cycles of bevacizumab with daily oral etoposide. The patient (Patient 13, Table 1) initially presented with grade I fibroblastic meningioma treated with resection, adjuvant imatinib/hydroxyurea, and then temozolomide following first progression and did not receive prior radiotherapy. a Post-contrast axial T1-weighted images. b Post-contrast sagittal T1-weighted images